ICCM IceCure Medical Ltd
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.…
Industry Peers
Medical DevicesKey Statistics
About IceCure Medical (NASDAQ: ICCM)
›
IceCure Medical (NASDAQ: ICCM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 67 employees.
The shares were at 0.9971 USD on 19 November 2026, down 95.2% over 52 weeks. Its 52-week range is 0.6525 USD to 22.50 USD: the price is 95.6% below the high and 52.8% above the low.
Its market capitalisation is 4.62M USD.
IceCure Medical reports return on equity of -166.4%, an operating margin of -423.7% and revenue up 72.8% year over year.
It holds more cash than debt, a net cash position of 11.94M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.